Nona Biosciences Enhances Discovery-to-Clinical Framework for Trials

Nona Biosciences, a biotechnology firm based in Cambridge, Massachusetts, announced on December 24, 2025, a significant expansion of its integrated discovery and development framework. This enhancement aims to bolster early clinical development and support Investigator-Initiated Trials (IITs). By broadening its capabilities beyond initial discovery and Investigational New Drug (IND) enabling activities, Nona seeks to improve its chemistry, manufacturing, and controls (CMC) development, toxicology, and Good Manufacturing Practice (GMP) manufacturing processes.

The company’s latest initiatives are designed to help global biopharmaceutical companies expedite the initiation of clinical trials while adhering to rigorous scientific and quality standards. Nona’s expanded framework builds on its proprietary technology platforms, including the innovative Harbour Mice ®, HBICE ®, Hu-mAtrIxTM, NonaCarFxTM, and Modalities-on-DemandTM. These platforms integrate enhanced preclinical and early clinical development capabilities, further strengthening the company’s position in the biotechnology sector.

By forming strategic partnerships and acquiring new platforms, as well as innovating internally, Nona aims to facilitate faster clinical trial initiation. The company’s partnerships, particularly in China, provide access to established infrastructures and operational efficiencies. This approach is expected to maintain high standards of global development and regulatory compliance, which are crucial for successful clinical trials.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, emphasized the importance of this expansion. “Expanding Nona’s technology platforms and capabilities from antibody discovery to early clinical development represents a natural progression of our strategic vision,” he stated. Dr. Hong noted that by merging proprietary platforms with strategic collaborations, Nona is enhancing its capacity for efficient clinical translation while focusing on differentiated and scalable technologies.

Nona Biosciences has considerable experience, having engaged in over 300 discovery programs and developed a growing portfolio of clinically validated platforms. The company positions itself as a leader in biologic innovation, aiming to empower partners to transition from discovery to early clinical development through its integrated, high-performance platforms.

The company’s proprietary Harbour Mice ® technology platform is particularly noteworthy. It generates fully human monoclonal antibodies in both classical two light and two heavy chain (H2L2) format, as well as heavy chain-only (HCAb) format. The HCAb Harbour Mice ® is recognized as the world’s first fully human HCAb transgenic mouse with clinical validation, presenting significant versatility for numerous applications.

Nona’s capabilities extend beyond antibody generation. Its platforms support various therapeutic innovations, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), and mRNA-based therapeutics. The integration of Harbour Mice ® with single-B cell screening technology, the direct CAR-function-based screening platform NonaCarFxTM, and the AI-driven drug discovery platform Hu-mAtrIxTM reflects Nona’s commitment to advancing transformative drug development.

By providing end-to-end preclinical drug development services and innovative next-generation modalities, Nona Biosciences is dedicated to pioneering the global landscape of biotherapeutic innovations. The company’s efforts aim to not only enhance the efficiency of drug development but also to ensure that high-quality standards are met throughout the process.

For further information about Nona Biosciences and its offerings, please visit their website at www.nonabio.com.